BioCentury
ARTICLE | Clinical News

Ampio falls on Ampion update, possible BLA delay

August 22, 2014 12:28 AM UTC

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) fell $1.80 (24%) to $5.66 on Thursday after announcing it will report data from the Phase III STEP trial of Ampion to treat osteoarthritis (OA) of the knee later than previously expected. Top-line data from the trial were originally expected this quarter, with a BLA submission slated for 1Q15. Ampio attributed the delay to the discovery by an independent CRO that both Ampion and placebo were exposed to "lower temperatures than permitted by the drug specifications" during shipment to trial sites. ...